In 2013, a phase I clinical trial in which ipilimumab (anti-CTLA-4 mAb) was combined with nivolumab (anti-PD1 mAb) reported tumor regression in 50% of treated patients [64]. This evidence concerns the gene CTLA4 and neoplasm.